Professor Johanna Olweus and her research team of 16 have received NOK 4.5 million in grants from the Danish Novo Nordisk Foundation. The money will be used to commercialize a whole new type of cancer immunotherapy that Olweus and her team are developing.
They have found a way to program cancer patients' immune cells to fight cancer using healthy human immune cells. This method allows the immune system to attack the cancer cells specifically, without harming other cells.
From major journals, first or last author from the Institute for Cancer Research
Protrudin-mediated ER-endosome contact sites promote MT1-MMP exocytosis and cell invasion
J Cell Biol, 219 (8)
Diacylglycerol kinase and phospholipase D inhibitors alter the cellular lipidome and endosomal sorting towards the Golgi apparatus
Cell Mol Life Sci (in press)
The role of lipid species in membranes and cancer-related changes
Cancer Metastasis Rev